Welcome to our dedicated page for Nvidia news (Ticker: NVDA), a resource for investors and traders seeking the latest updates and insights on Nvidia stock.
NVIDIA Corporation develops graphics processing units, accelerated computing systems, and software platforms used in gaming, artificial intelligence, data centers, and AI model development. Company news around NVDA commonly covers financial results, data center demand, AI infrastructure partnerships, networking and optical-connectivity collaborations, and platform launches such as NVIDIA Ising and NVLink Fusion.
Updates also address NVIDIA’s AI factory architecture, systems that connect GPUs for large workloads, quantum-computing tools for calibration and error correction, and governance changes involving the board, audit committee, and executive finance roles.
NVIDIA has appointed Aarti Shah to its board of directors, expanding the board to 13 members. Shah, who is the senior vice president and chief information and digital officer at Eli Lilly and Company, brings extensive experience in IT, digital health, and analytics. Jensen Huang, NVIDIA's CEO, highlighted her as a world-class leader poised to enhance the intersection of computer science and healthcare. This marks the second board addition in 2020, following the July appointment of John Dabiri.
NVIDIA is set to host a conference call on November 18, 2020, at 2 p.m. PT to discuss its Q3 fiscal year 2021 results, ending October 25, 2020. The call will be available in listen-only mode on NVIDIA's website. Written commentary from the CFO will be released shortly before the call, available on investor.nvidia.com. The conference call will provide insights into NVIDIA's financial performance and future outlook.
NVIDIA has extended its leadership in AI performance, achieving unprecedented results in the recent MLPerf benchmark. The A100 Tensor Core GPU outperformed CPUs by up to 237x in new inference tests, leading across all six application areas. Industries are increasingly adopting NVIDIA's AI solutions, with its GPUs now offering more AI inference capacity in the cloud than CPUs. The advancements provide significant cost efficiency for businesses, enabling seamless transitions from research to operational AI.
NVIDIA announced that the Italian consortium CINECA will build the world’s fastest AI supercomputer, named Leonardo, utilizing NVIDIA's accelerated computing platform. This system aims to deliver 10 exaflops of AI performance, enhancing Italy’s leadership in AI and high-performance computing (HPC) research. Funded by the European Commission, Leonardo is designed to tackle scientific challenges across various fields including drug discovery and climate change, leveraging NVIDIA's Ampere architecture GPUs and advanced networking technology.
NVIDIA has unveiled its new data processing units (DPUs) and the DOCA SDK, aimed at revolutionizing data center infrastructure. CEO Jensen Huang emphasized that DPUs are essential for modern data centers, enabling organizations to enhance their IT infrastructure with superior networking, storage, and security. A single BlueField-2 DPU can replace up to 125 CPU cores, streamlining operations. Major server manufacturers like ASUS and Dell are set to adopt NVIDIA's DPUs, which are optimized for AI and security tasks. The DOCA SDK will help developers create applications for these DPU-accelerated environments.
NVIDIA has partnered with GSK to establish a pioneering AI hub in London, utilizing advanced computing and AI methods for drug and vaccine discovery. This hub will integrate GSK’s genetic data with NVIDIA's DGX A100 systems and the Cambridge-1 supercomputer to enhance drug development precision. Dr. Kim Branson emphasized the need for advanced algorithms due to large datasets. NVIDIA’s contributions include expertise in GPU optimization, bolstering GSK's efforts to redefine data-driven medicine and improve research outcomes.
NVIDIA has launched the open beta of its Omniverse platform, aimed at enabling real-time collaboration for designers, architects, and creators globally. This follows a yearlong early access program with over 40 companies, including Ericsson and Lucasfilm. The platform leverages NVIDIA's advanced graphics and simulation technologies to merge physical and virtual worlds, enhancing project collaboration in various industries, such as robotics and media. Omniverse supports Pixar's Universal Scene Description format, allowing seamless interoperability between applications.
NVIDIA has introduced the Jetson Nano 2GB Developer Kit priced at $59, designed to make AI accessible for students, educators, and hobbyists. This kit is part of the Jetson AI at the Edge platform, enabling hands-on learning in robotics and IoT. Accompanying free online training and AI-certification programs aim to enhance educational resources. Endorsements from industry leaders underscore its potential in driving AI learning.
The kit will be available by the end of the month through NVIDIA’s distribution channels.
NVIDIA has launched the NVIDIA Maxine, a cloud-based AI platform designed for enhancing video conferencing quality. This GPU-accelerated solution allows developers to offer advanced features like gaze correction, super-resolution, and noise cancellation for over 30 million daily web meetings. Maxine's technology reduces video bandwidth consumption by up to 90% compared to H.264, enabling smoother calls without special hardware. It integrates NVIDIA's various SDKs, making it easier for developers to implement AI enhancements into their services.
NVIDIA announced the development of the U.K.'s most powerful supercomputer, Cambridge-1, designed for healthcare researchers to address significant medical challenges, including COVID-19. Slated to be operational by year-end, it will deliver over 400 petaflops of AI performance. Key pharmaceutical companies like GSK and AstraZeneca will utilize this system. NVIDIA is investing around £40 million in this initiative, establishing it as a hub for innovation in healthcare research, education, and AI startups. The project represents a substantial step for healthcare advances in the U.K.